University of Texas Medical Branch at Galveston, Institute for Translational Sciences

Mission Statement
At a Glance
0
Educational Resources Posted
0
Consortium News Stories Posted
0
Events Posted
2
Opportunities Posted
380
Publications citing CTSA Program Grant
29
Users from Hub Registered
UL1 Award
KL2 Award
TL1 Award
UL1
UL1 Director
RandallUrbanVice President and Chief Research OfficerUL1 Administrator
LoriWisemanAssociate Director for Administration, Institute for Translational SciencesEducation
KL2 Director
KL2 Administrator
TL1 Director
TL1 Administrator
Communications
Communications Representative
Enterprise Committees
Integration Across Lifespan Voting Member
Methods and Processes Voting Member
KevinWootenConsulting Director of Tracking and EvaluationWorkforce Development Voting Member
Informatics Voting Member
Collaboration and Engagement Voting Member
Common Metrics
Primary CM Contact
KevinWootenConsulting Director of Tracking and EvaluationAdditional CM Contacts
- ToniD'AgostinoSenior Advisor to the Chief Research Officer
- ClaudiaDelgadoDirector Grants and Contracts Accounting, AVP Research Administration
- VictoriaMcNamaraResearch Regulatory Specialist- Institute for Translational Research
- RandallUrbanVice President and Chief Research Officer
- LoriWisemanAssociate Director for Administration, Institute for Translational Sciences
- KevinWootenConsulting Director of Tracking and Evaluation
Opportunities
Poster Sessions
Discovering drugs with the potential to prevent and treat disease takes many years for teams to progress from target validation through initial hits identification, lead optimization, and selection of a candidate for clinical trials. Diseases for which a drug would yield low commercial returns (
CTSA resources are vital to our Hub’s efforts to understand SARS-CoV-2 infection and to prevent and treat COVID-19. In partnership with institutional leadership, our CTSA launched a rapid, multifaceted response protocol to advance the work of Pei-Yong Shi, PhD and his team, who had been working with the Galveston National Laboratory to develop a high throughput assay platform for neutralizing

Since 2009, we have promoted translational entrepreneurial activities at our CTSA Hub, with an emphasis on engaging scholars and trainees. We are building a culture of innovation and entrepreneurship, as a way to enhance discovery and translation of products that improve health. As an optional function of our second CTSA, we developed the Innovations in Molecular Therapeutics and Devices (IMTD)
Publications
Surrogate post-coital testing for contraceptive efficacy against human sperm activity in the ovine vaginal model†
High unintended pregnancy rates are partially due to lack of effective nonhormonal contraceptives; development of safe, effective topical vaginal methods will address this need. Preclinical product safety and efficacy assessment requires in vivo testing in appropriate models. The sheep is a good
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera
We engineered three SARS-CoV-2 viruses containing key spike mutations from the newly emerged United Kingdom (UK) and South African (SA) variants: N501Y from UK and SA; 69/70-deletion+N501Y+D614G from UK; and E484K+N501Y+D614G from SA. Neutralization geometric mean titers (GMTs) of twenty BTN162b2
Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor. We generated isogenic
Title | Authored Sort ascending | Content type |
---|---|---|
Opportunity: Drug Discovery in Academia | November 05, 2021 | Poster |
Optimizing COVID-19 Research with CTSA Resources | October 22, 2020 | Poster |
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults | April 20, 2020 | Covid Study |
Sr. Manager of Research Operations - Center for Addiction Research | October 16, 2019 | Opportunity |
Research Ethicist | September 30, 2019 | Opportunity |
Building capacity for entrepreneurship and commercialization | August 23, 2019 | Poster |
UNIVERSITY OF TEXAS MED BR GALVESTON | February 05, 2019 | CTSA Program Hub |